| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Review
- Language: English
- [Eur J Heart Fail] 2024 Feb; Vol. 26 (2), pp. 460-470. <i>Date of Electronic Publication: </i>2024 Jan 31.
- MeSH Terms: Transcatheter Aortic Valve Replacement* ; Aortic Valve Stenosis* / complications ; Aortic Valve Stenosis* / surgery ; Heart Failure* / complications ; Heart Failure* / surgery ; Humans ; Quality of Life ; Treatment Outcome ; Aortic Valve / surgery ; Risk Factors ; Severity of Illness Index ; Ventricular Function, Left
- References: Ross J, Braunwald E. Aortic stenosis. Circulation 1968;38:61–67. https://doi.org/10.1161/01.CIR.38.1S5.V‐61. ; Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021;77:450–500. https://doi.org/10.1016/j.jacc.2020.11.035. ; Généreux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, et al. Staging classification of aortic stenosis based on the extent of cardiac damage. Eur Heart J 2017;38:3351–3358. https://doi.org/10.1093/eurheartj/ehx381. ; Biner S, Birati EY, Topilsky Y, Steinvil A, Ben Assa E, Sadeh B, et al. Outcome of transcatheter aortic valve implantation in patients with low‐gradient severe aortic stenosis and preserved left ventricular ejection fraction. Am J Cardiol 2014;113:348–354. https://doi.org/10.1016/j.amjcard.2013.08.048. ; Baron SJ, Arnold SV, Herrmann HC, Holmes DR, Szeto WY, Allen KB, et al. Impact of ejection fraction and aortic valve gradient on outcomes of transcatheter aortic valve replacement. J Am Coll Cardiol 2016;67:2349–2358. https://doi.org/10.1016/j.jacc.2016.03.514. ; Durand E, Doutriaux M, Bettinger N, Tron C, Fauvel C, Bauer F, et al. Incidence, prognostic impact, and predictive factors of readmission for heart failure after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2017;10:2426–2436. https://doi.org/10.1016/j.jcin.2017.09.010. ; Barbash IM, Minha S, Ben‐Dor I, Dvir D, Magalhaes MA, Torguson R, et al. Relation of preprocedural assessment of myocardial contractility reserve on outcomes of aortic stenosis patients with impaired left ventricular function undergoing transcatheter aortic valve implantation. Am J Cardiol 2014;113:1536–1542. https://doi.org/10.1016/j.amjcard.2014.01.433. ; Furer A, Chen S, Redfors B, Elmariah S, Pibarot P, Herrmann HC, et al. Effect of baseline left ventricular ejection fraction on 2‐year outcomes after transcatheter aortic valve replacement: Analysis of the PARTNER 2 trials. Circ Heart Fail 2019;12:e005809. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005809. ; Ribeiro HB, Lerakis S, Gilard M, Cavalcante JL, Makkar R, Herrmann HC, et al. Transcatheter aortic valve replacement in patients with low‐flow, low‐gradient aortic stenosis: The TOPAS‐TAVI registry. J Am Coll Cardiol 2018;71:1297–1308. https://doi.org/10.1016/j.jacc.2018.01.054. ; O'Sullivan CJ, Stortecky S, Bütikofer A, Heg D, Zanchin T, Huber C, et al. Impact of mitral regurgitation on clinical outcomes of patients with low‐ejection fraction, low‐gradient severe aortic stenosis undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv 2015;8:e001895. https://doi.org/10.1161/CIRCINTERVENTIONS.114.001895. ; Ludwig S, Goßling A, Seiffert M, Westermann D, Sinning JM, Sugiura A, et al. Risk prediction in patients with low‐flow, low‐gradient aortic stenosis and reduced ejection fraction undergoing TAVI. Open Heart 2022;9:e001912. https://doi.org/10.1136/openhrt‐2021‐001912. ; Elmariah S, Fearon WF, Inglessis I, Vlahakes GJ, Lindman BR, Alu MC, et al.; PARTNER Trial Investigators and PARTNER Publications Office. Transapical transcatheter aortic valve replacement is associated with increased cardiac mortality in patients with left ventricular dysfunction: Insights from the PARTNER I trial. JACC Cardiovasc Interv 2017;10:2414–2422. https://doi.org/10.1016/j.jcin.2017.09.023. ; Amer MR, Mosleh W, Memon S, Joshi S, Sullivan B, Sharkawi M, et al. Comparison of benefit of transcatheter aortic valve implantation in patients with low gradient versus high gradient aortic stenosis and left ventricular dysfunction. Am J Cardiol 2020;125:1543–1549. https://doi.org/10.1016/j.amjcard.2020.02.019. ; Carabello BA. Where do low‐gradient, low‐EF AS patients come from?: Maybe they're born that way. J Am Coll Cardiol 2018;71:1322–1324. https://doi.org/10.1016/j.jacc.2018.01.041. ; Carabello BA, Green LH, Grossman W, Cohn LH, Koster JK, Collins JJJ. Hemodynamic determinants of prognosis of aortic valve replacement in critical aortic stenosis and advanced congestive heart failure. Circulation 1980;62:42–48. https://doi.org/10.1161/01.cir.62.1.42. ; O'Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Hosek N, Buellesfeld L, et al. Clinical outcomes of patients with low‐flow, low‐gradient, severe aortic stenosis and either preserved or reduced ejection fraction undergoing transcatheter aortic valve implantation. Eur Heart J 2013;34:3437–3450. https://doi.org/10.1093/eurheartj/eht408. ; Ito S, Miranda WR, Nkomo VT, Connolly HM, Pislaru SV, Greason KL, et al. Reduced left ventricular ejection fraction in patients with aortic stenosis. J Am Coll Cardiol 2018;71:1313–1321. https://doi.org/10.1016/j.jacc.2018.01.045. ; Angelillis M, Giannini C, De Carlo M, Adamo M, Nardi M, Colombo A, et al. Prognostic significance of change in the left ventricular ejection fraction after transcatheter aortic valve implantation in patients with severe aortic stenosis and left ventricular dysfunction. Am J Cardiol 2017;120:1639–1647. https://doi.org/10.1016/j.amjcard.2017.07.064. ; Kolte D, Bhardwaj B, Lu M, Alu MC, Passeri JJ, Inglessis I, et al. Association between early left ventricular ejection fraction improvement after transcatheter aortic valve replacement and 5‐year clinical outcomes. JAMA Cardiol 2022;7:934–944. https://doi.org/10.1001/jamacardio.2022.2222. ; Jeong YJ, Ahn JM, Kang DY, Park H, Ko E, Kim HJ, et al. Incidence, predictors, and prognostic impact of immediate improvement in left ventricular systolic function after transcatheter aortic valve implantation. Am J Cardiol 2021;152:99–105. https://doi.org/10.1016/j.amjcard.2021.04.037. ; Buchanan KD, Rogers T, Steinvil A, Koifman E, Xu L, Torguson R, et al. Role of contractile reserve as a predictor of mortality in low‐flow, low‐gradient severe aortic stenosis following transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2019;93:707–712. https://doi.org/10.1002/ccd.27914. ; Maes F, Lerakis S, Barbosa Ribeiro H, Gilard M, Cavalcante JL, Makkar R, et al. Outcomes from transcatheter aortic valve replacement in patients with low‐flow, low‐gradient aortic stenosis and left ventricular ejection fraction less than 30%: A substudy from the TOPAS‐TAVI registry. JAMA Cardiol 2019;4:64–70. https://doi.org/10.1001/jamacardio.2018.4320. ; Bavishi C, Trivedi V, Sellke FW, Gordon PC, Abbott JD. Myocardial contractile reserve and mortality in patients with severe aortic stenosis with impaired left ventricular function who underwent transcatheter aortic valve implantation. Am J Cardiol 2021;141:150–152. https://doi.org/10.1016/j.amjcard.2020.11.023. ; van Gils L, Clavel MA, Vollema EM, Hahn RT, Spitzer E, Delgado V, et al. Prognostic implications of moderate aortic stenosis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2017;69:2383–2392. https://doi.org/10.1016/j.jacc.2017.03.023. ; Jean G, Van Mieghem NM, Gegenava T, van Gils L, Bernard J, Geleijnse ML, et al. Moderate aortic stenosis in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2021;77:2796–2803. https://doi.org/10.1016/j.jacc.2021.04.014. ; Ludwig S, Schofer N, Abdel‐Wahab M, Urena M, Jean G, Renker M, et al. Transcatheter aortic valve replacement in patients with reduced ejection fraction and nonsevere aortic stenosis. Circ Cardiovasc Interv 2023;16:e012768. https://doi.org/10.1161/CIRCINTERVENTIONS.122.012768. ; Ahmed A, Alsidawi S, Bae R, Cavalcante J, Fukui M, Gössl M, et al. Changes in quality of life in patients with low‐flow aortic stenosis undergoing transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2020;96:972–978. https://doi.org/10.1002/ccd.28805. ; Wagener M, Reuthebuch O, Heg D, Tüller D, Ferrari E, Grünenfelder J, et al. Clinical outcomes in high‐gradient, classical low‐flow, low‐gradient, and paradoxical low‐flow, low‐gradient aortic stenosis after transcatheter aortic valve implantation: A report from the SwissTAVI registry. J Am Heart Assoc 2023;12:e029489. https://doi.org/10.1161/JAHA.123.029489. ; Mosleh W, Amer MR, Ding Y, Megaly M, Mather JF, McMahon S, et al. Benefit of transcatheter aortic valve replacement in patients with paradoxical low‐flow low‐gradient versus high‐gradient aortic stenosis and preserved left ventricular function. Circ Cardiovasc Interv 2021;14:e010042. https://doi.org/10.1161/CIRCINTERVENTIONS.120.010042. ; Popovic B, Molho A, Varlot J, Fay R, Metzdorf PA, Elfarra M, et al. Prognostic influence of acute decompensated heart failure in patients planned for transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2020;96:E542–E551. https://doi.org/10.1002/ccd.28813. ; Tang L, Gössl M, Ahmed A, Garberich R, Bradley SM, Niikura H, et al. Contemporary reasons and clinical outcomes for patients with severe, symptomatic aortic stenosis not undergoing aortic valve replacement. Circ Cardiovasc Interv 2018;11:e007220. https://doi.org/10.1161/CIRCINTERVENTIONS.118.007220. ; Jalava MP, Laakso T, Virtanen M, Niemelä M, Ahvenvaara T, Tauriainen T, et al. Transcatheter and surgical aortic valve replacement in patients with recent acute heart failure. Ann Thorac Surg 2020;109:110–117. https://doi.org/10.1016/j.athoracsur.2019.05.044. ; Kaewkes D, Ochiai T, Flint N, Patel V, Patel J, Kim I, et al. Transcatheter aortic valve implantation in patients with severe aortic stenosis hospitalized with acute heart failure. Am J Cardiol 2021;144:100–110. https://doi.org/10.1016/j.amjcard.2020.12.046. ; Chen S, Redfors B, Crowley A, Ben‐Yehuda O, Summers M, Hahn RT, et al. Impact of recent heart failure hospitalization on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: An analysis from the PARTNER 2 trial and registries. Eur J Heart Fail 2020;22:1866–1874. https://doi.org/10.1002/ejhf.1841. ; Asgar AW, Ouzounian M, Adams C, Afilalo J, Fremes S, Lauck S, et al. 2019 Canadian Cardiovascular Society position statement for transcatheter aortic valve implantation. Can J Cardiol 2019;35:1437–1448. https://doi.org/10.1016/j.cjca.2019.08.011. ; Asami M, Stortecky S, Praz F, Lanz J, Räber L, Franzone A, et al. Prognostic value of right ventricular dysfunction on clinical outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Imaging 2019;12:577–587. https://doi.org/10.1016/j.jcmg.2017.12.015. ; Durand E, Sacri C, Levesque T, Tron C, Barbe T, Hemery T, et al. Incidence, predictive factors, and prognostic impact of right ventricular dysfunction before transcatheter aortic valve implantation. Am J Cardiol 2021;161:63–69. https://doi.org/10.1016/j.amjcard.2021.08.068. ; Généreux P, Pibarot P, Redfors B, Bax JJ, Zhao Y, Makkar RR, et al. Evolution and prognostic impact of cardiac damage after aortic valve replacement. J Am Coll Cardiol 2022;80:783–800. https://doi.org/10.1016/j.jacc.2022.05.006. ; Grevious SN, Fernandes MF, Annor AK, Ibrahim M, Saint Croix GR, de Marchena E, et al. Prognostic assessment of right ventricular systolic dysfunction on post‐transcatheter aortic valve replacement short‐term outcomes: Systematic review and meta‐analysis. J Am Heart Assoc 2020;9:e014463. https://doi.org/10.1161/JAHA.119.014463. ; Granot Y, Merdler I, Finkelstein A, Arbel Y, Banai S, Topilsky Y, et al. Prognostic implication of right ventricular dysfunction and tricuspid regurgitation following transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2021;98:E758–E767. https://doi.org/10.1002/ccd.29639. ; Tarantini G, Tang G, Nai Fovino L, Blackman D, Van Mieghem NM, Kim WK, et al. Management of coronary artery disease in patients undergoing transcatheter aortic valve implantation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions in collaboration with the ESC Working Group on Cardiovascular Surgery. EuroIntervention 2023;19:37–52. https://doi.org/10.4244/EIJ‐D‐22‐00958. ; Costa G, Pilgrim T, Amat Santos IJ, De Backer O, Kim WK, Barbosa Ribeiro H, et al.; REVASC‐TAVI Registry. Management of myocardial revascularization in patients with stable coronary artery disease undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv 2022;15:e012417. https://doi.org/10.1161/CIRCINTERVENTIONS.122.012417. ; Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, et al.; ACTIVATION Trial Investigators. ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION): A randomized clinical trial. JACC Cardiovasc Interv 2021;14:1965–1974. https://doi.org/10.1016/j.jcin.2021.06.041. ; Webb JG, Mack MJ, White JM, Dvir D, Blanke P, Herrmann HC, et al. Transcatheter aortic valve implantation within degenerated aortic surgical bioprostheses: PARTNER 2 valve‐in‐valve registry. J Am Coll Cardiol 2017;69:2253–2262. https://doi.org/10.1016/j.jacc.2017.02.057. ; Hahn RT, Webb J, Pibarot P, Ternacle J, Herrmann HC, Suri RM, et al. 5‐year follow‐up from the PARTNER 2 aortic valve‐in‐valve registry for degenerated aortic surgical bioprostheses. JACC Cardiovasc Interv 2022;15:698–708. https://doi.org/10.1016/j.jcin.2022.02.014. ; Akodad M, Meilhac A, Lefèvre T, Cayla G, Lattuca B, Autissier C, et al. Hemodynamic performances and clinical outcomes in patients undergoing valve‐in‐valve versus native transcatheter aortic valve implantation. Am J Cardiol 2019;124:90–97. https://doi.org/10.1016/j.amjcard.2019.04.009. ; Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879–2887. https://doi.org/10.1093/eurheartj/ehx350. ; Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol 2021;77:128–139. https://doi.org/10.1016/j.jacc.2020.11.006. ; Nitsche C, Aschauer S, Kammerlander AA, Schneider M, Poschner T, Duca F, et al. Light‐chain and transthyretin cardiac amyloidosis in severe aortic stenosis: Prevalence, screening possibilities, and outcome. Eur J Heart Fail 2020;22:1852–1862. https://doi.org/10.1002/ejhf.1756. ; Shimoni S, Zikri M, Haberman D, Livschitz S, Tshori S, Fabricant Y, et al. Transthyretin cardiac amyloidosis in patients after TAVR: Clinical and echocardiographic findings and long term survival. ESC Heart Fail 2021;8:4549–4561. https://doi.org/10.1002/ehf2.13667. ; Truby LK, Garan AR, Givens RC, Wayda B, Takeda K, Yuzefpolskaya M, et al. Aortic insufficiency during contemporary left ventricular assist device support: Analysis of the INTERMACS registry. JACC Heart Fail 2018;6:951–960. https://doi.org/10.1016/j.jchf.2018.07.012. ; Soleimani B, Haouzi A, Manoskey A, Stephenson ER, El‐Banayosy A, Pae WE. Development of aortic insufficiency in patients supported with continuous flow left ventricular assist devices. ASAIO J 2012;58:326–329. https://doi.org/10.1097/MAT.0b013e318251cfff. ; Danley MR, Lensing C, Eagle SS, Kingeter MA. Transcatheter aortic valve replacement in patients with left ventricular assist devices and aortic regurgitation‐single institution retrospective analysis. J Cardiothorac Vasc Anesth 2022;36:2839–2840. https://doi.org/10.1053/j.jvca.2022.03.020. ; Pesarini G, Lunardi M, Piccoli A, Gottin L, Prati D, Ferrero V, et al. Effectiveness and safety of transcatheter aortic valve implantation in patients with pure aortic regurgitation and advanced heart failure. Am J Cardiol 2018;121:642–648. https://doi.org/10.1016/j.amjcard.2017.11.042. ; Dhillon AS, Jones BM, Hodson RW, Korngold EC. Transcatheter aortic valve replacement for severe aortic regurgitation in patients with a left ventricular assist device. J Invasive Cardiol 2022;34:E369–E373. ; Urena M, Webb JG, Eltchaninoff H, Muñoz‐García AJ, Bouleti C, Tamburino C, et al. Late cardiac death in patients undergoing transcatheter aortic valve replacement: Incidence and predictors of advanced heart failure and sudden cardiac death. J Am Coll Cardiol 2015;65:437–448. https://doi.org/10.1016/j.jacc.2014.11.027. ; Auffret V, Bakhti A, Leurent G, Bedossa M, Tomasi J, Belhaj Soulami R, et al. Determinants and impact of heart failure readmission following transcatheter aortic valve replacement. Circ Cardiovasc Interv 2020;13:e008959. https://doi.org/10.1161/CIRCINTERVENTIONS.120.008959. ; Nazzari H, Hawkins NM, Ezekowitz J, Lauck S, Ding L, Polderman J, et al. The relationship between heart‐failure hospitalization and mortality in patients receiving transcatheter aortic valve replacement. Can J Cardiol 2019;35:413–421. https://doi.org/10.1016/j.cjca.2018.11.016. ; Theron A, Lavagna F, Gaubert G, Resseguier N, Porto A, Ferrara J, et al. Prosthesis‐patient mismatch is an independent predictor of congestive heart failure after transcatheter aortic valve replacement. Arch Cardiovasc Dis 2021;114:504–514. https://doi.org/10.1016/j.acvd.2020.11.005. ; Carrabba N, Valenti R, Migliorini A, Marrani M, Cantini G, Parodi G, et al. Impact on left ventricular function and remodeling and on 1‐year outcome in patients with left bundle branch block after transcatheter aortic valve implantation. Am J Cardiol 2015;116:125–131. https://doi.org/10.1016/j.amjcard.2015.03.054. ; Tzikas A, van Dalen BM, Van Mieghem NM, Gutierrez‐Chico JL, Nuis RJ, Kauer F, et al. Frequency of conduction abnormalities after transcatheter aortic valve implantation with the Medtronic‐CoreValve and the effect on left ventricular ejection fraction. Am J Cardiol 2011;107:285–289. https://doi.org/10.1016/j.amjcard.2010.09.015. ; Sammour Y, Krishnaswamy A, Kumar A, Puri R, Tarakji KG, Bazarbashi N, et al. Incidence, predictors, and implications of permanent pacemaker requirement after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2021;14:115–134. https://doi.org/10.1016/j.jcin.2020.09.063. ; Pagnesi M, Kim WK, Baggio S, Scotti A, Barbanti M, De Marco F, et al. Incidence, predictors, and prognostic impact of new permanent pacemaker implantation after TAVR with self‐expanding valves. JACC Cardiovasc Interv 2023;16:2004–2017. https://doi.org/10.1016/j.jcin.2023.05.020. ; Fadahunsi OO, Olowoyeye A, Ukaigwe A, Li Z, Vora AN, Vemulapalli S, et al. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: Analysis from the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry. JACC Cardiovasc Interv 2016;9:2189–2199. https://doi.org/10.1016/j.jcin.2016.07.026. ; Chamandi C, Barbanti M, Munoz‐Garcia A, Latib A, Nombela‐Franco L, Gutiérrez‐Ibanez E, et al. Long‐term outcomes in patients with new permanent pacemaker implantation following transcatheter aortic valve replacement. JACC Cardiovasc Interv 2018;11:301–310. https://doi.org/10.1016/j.jcin.2017.10.032. ; Tsushima T, Al‐Kindi S, Palma Dallan LA, Fares A, Yoon SH, Wheat HL, et al. Clinical impact of right ventricular pacing burden in patients with post‐transcatheter aortic valve replacement permanent pacemaker implantation. Europace 2023;25:1441–1450. https://doi.org/10.1093/europace/euad025. ; Ochiai T, Yamanaka F, Shishido K, Moriyama N, Komatsu I, Yokoyama H, et al. Impact of high implantation of transcatheter aortic valve on subsequent conduction disturbances and coronary access. JACC Cardiovasc Interv 2023;16:1192–1204. https://doi.org/10.1016/j.jcin.2023.03.021. ; Arnold SV, Manandhar P, Vemulapalli S, Vekstein AM, Kosinski AS, Spertus JA, et al. Patient‐reported vs. physician‐estimated symptoms before and after transcatheter aortic valve replacement. Eur Heart J Qual Care Clin Outcomes 2022;8:161–168. https://doi.org/10.1093/ehjqcco/qcab078. ; Arnold SV, Spertus JA, Vemulapalli S, Li Z, Matsouaka RA, Baron SJ, et al. Quality‐of‐life outcomes after transcatheter aortic valve replacement in an unselected population: A report from the STS/ACC Transcatheter Valve Therapy Registry. JAMA Cardiol 2017;2:409–416. https://doi.org/10.1001/jamacardio.2016.5302. ; Osnabrugge RL, Arnold SV, Reynolds MR, Magnuson EA, Wang K, Gaudiani VA, et al.; CoreValve U.S. Trial Investigators. Health status after transcatheter aortic valve replacement in patients at extreme surgical risk: Results from the CoreValve U.S. trial. JACC Cardiovasc Interv 2015;8:315–323. https://doi.org/10.1016/j.jcin.2014.08.016. ; Arnold SV, Manandhar P, Vemulapalli S, Kosinski A, Desai ND, Bavaria JE, et al. Impact of short‐term complications of transcatheter aortic valve replacement on longer‐term outcomes: Results from the STS/ACC Transcatheter Valve Therapy Registry. Eur Heart J Qual Care Clin Outcomes 2021;7:208–213. https://doi.org/10.1093/ehjqcco/qcaa001. ; Phuong N, Solomon RJ, DeSarno MJ, LeWinter MM, Zimmer J, Dauerman HL. Acute kidney injury and renin‐angiotensin system inhibition following transcatheter aortic valve replacement. J Invasive Cardiol 2021;33:E662–E669. ; Chen S, Redfors B, Nazif T, Kirtane A, Crowley A, Ben‐Yehuda O, et al. Impact of renin‐angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: An analysis of from the PARTNER 2 trial and registries. Eur Heart J 2020;41:943–954. https://doi.org/10.1093/eurheartj/ehz769. ; Rodriguez‐Gabella T, Catalá P, Muñoz‐García AJ, Nombela‐Franco L, Del Valle R, Gutiérrez E, et al. Renin‐angiotensin system inhibition following transcatheter aortic valve replacement. J Am Coll Cardiol 2019;74:631–641. https://doi.org/10.1016/j.jacc.2019.05.055. ; Inohara T, Manandhar P, Kosinski AS, Matsouaka RA, Kohsaka S, Mentz RJ, et al. Association of renin‐angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement. JAMA 2018;320:2231–2241. https://doi.org/10.1001/jama.2018.18077. ; Ledwoch J, Olbrich I, Poch F, Thalmann R, Fellner C, Stundl A, et al. Dose‐dependent effect of renin‐angiotensin system blockade following transcatheter aortic valve replacement. Can J Cardiol 2021;37:443–449. https://doi.org/10.1016/j.cjca.2020.08.014. ; Sun Y, Li J, Li G, Fan R, Luo J. Impact of renin‐angiotensin system inhibitors on outcomes after transcatheter aortic valve replacement: A meta‐analysis. Catheter Cardiovasc Interv 2021;97:E88–E94. https://doi.org/10.1002/ccd.28899. ; Amat‐Santos IJ, Catalá P, Diez Del Hoyo F, Fernandez‐Diaz JA, Alonso‐Briales JH, Del Trigo M, et al. Impact of renin‐angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: Rationale and design of the RASTAVI randomised multicentre study. BMJ Open 2018;8:e020255. https://doi.org/10.1136/bmjopen‐2017‐020255. ; Liao YB, Xia C, Cheng Y, Li Q, Wei X, Ou Y, et al. Angiotensin‐converting enzyme inhibitor for post‐transcatheter aortic valve implantation patients: Study protocol for a multicenter randomized, open‐label blinded endpoint control trial. Trials 2021;22:462. https://doi.org/10.1186/s13063‐021‐05411‐5. ; Amat‐Santos IJ, Sánchez‐Luna JP, Abu‐Assi E, Melendo‐Viu M, Cruz‐Gonzalez I, Nombela‐Franco L, et al.; Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) Investigators. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial. Eur J Heart Fail 2022;24:581–588. https://doi.org/10.1002/ejhf.2370. ; Saito T, Yoshijima N, Hase H, Yashima F, Tsuruta H, Shimizu H, et al. Impact of beta blockers on patients undergoing transcatheter aortic valve replacement: The OCEAN‐TAVI registry. Open Heart 2020;7:e001269. https://doi.org/10.1136/openhrt‐2020‐001269. ; Younis A, Orvin K, Nof E, Barabash IM, Segev A, Berkovitch A, et al. The effect of periprocedural beta blocker withdrawal on arrhythmic risk following transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2019;93:1361–1366. https://doi.org/10.1002/ccd.28017. ; Beohar N, Whisenant B, Kirtane AJ, Leon MB, Tuzcu EM, Makkar R, et al. The relative performance characteristics of the logistic European System for Cardiac Operative Risk Evaluation score and the Society of Thoracic Surgeons score in the Placement of Aortic Transcatheter Valves trial. J Thorac Cardiovasc Surg 2014;148:2830–2837.e1. https://doi.org/10.1016/j.jtcvs.2014.04.006. ; Edwards FH, Cohen DJ, O'Brien SM, Peterson ED, Mack MJ, Shahian DM, et al.; Steering Committee of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Development and validation of a risk prediction model for in‐hospital mortality after transcatheter aortic valve replacement. JAMA Cardiol 2016;1:46–52. https://doi.org/10.1001/jamacardio.2015.0326. ; Codner P, Malick W, Kouz R, Patel A, Chen CH, Terre J, et al. Mortality risk after transcatheter aortic valve implantation: Analysis of the predictive accuracy of the Transcatheter Valve Therapy registry risk assessment model. EuroIntervention 2018;14:e405–e412. https://doi.org/10.4244/EIJ‐D‐18‐00032. ; Arsalan M, Weferling M, Hecker F, Filardo G, Kim WK, Pollock BD, et al. TAVI risk scoring using established versus new scoring systems: Role of the new STS/ACC model. EuroIntervention 2018;13:1520–1526. https://doi.org/10.4244/EIJ‐D‐17‐00421. ; Lantelme P, Lacour T, Bisson A, Herbert J, Ivanes F, Bourguignon T, et al. Futility risk model for predicting outcome after transcatheter aortic valve implantation. Am J Cardiol 2020;130:100–107. https://doi.org/10.1016/j.amjcard.2020.05.043. ; Thourani VH, O'Brien SM, Kelly JJ, Cohen DJ, Peterson ED, Mack MJ, et al. Development and application of a risk prediction model for in‐hospital stroke after transcatheter aortic valve replacement: A report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Ann Thorac Surg 2019;107:1097–1103. https://doi.org/10.1016/j.athoracsur.2018.11.013. ; Navarese EP, Zhang Z, Kubica J, Andreotti F, Farinaccio A, Bartorelli AL, et al.; a Joint Effort of the Italian and Polish Cardiac Interventional Societies. Development and validation of a practical model to identify patients at risk of bleeding after TAVR. JACC Cardiovasc Interv 2021;14:1196–1206. https://doi.org/10.1016/j.jcin.2021.03.024. ; Tsushima T, Nadeem F, Al‐Kindi S, Clevenger JR, Bansal EJ, Wheat HL, et al. Risk prediction model for cardiac implantable electronic device implantation after transcatheter aortic valve replacement. JACC Clin Electrophysiol 2020;6:295–303. https://doi.org/10.1016/j.jacep.2019.10.020.
- Contributed Indexing: Keywords: Aortic stenosis; Ejection fraction; Heart failure; Transcatheter aortic valve intervention; Transcatheter aortic valve replacement
- Entry Date(s): Date Created: 20240201 Date Completed: 20240327 Latest Revision: 20240327
- Update Code: 20240327
|
